"2015-01-22+01:00"^^ . . . "2014-03-21+01:00"^^ . . . . "Modulation of Colorectal Carcinoma by Biological Therapy - In Vitro Study"@en . . "U pacient\u016F s provedenou resekc\u00ED kolorekt\u00E1ln\u00EDho karcinomu bude v r\u00E1mci rutinn\u00EDho histopatologick\u00E9ho vy\u0161et\u0159en\u00ED proveden okam\u017Eit\u00FD odb\u011Br n\u00E1dorov\u00E9 tk\u00E1n\u011B ke kryokonzervaci. Tk\u00E1\u0148 se po odebr\u00E1n\u00ED ulo\u017E\u00ED do transportn\u00EDho media tak, aby se omezil vliv hypoxie a ostatn\u00EDch vn\u011Bj\u0161\u00EDch vliv\u016F. N\u00E1dorov\u00E9 bu\u0148ky budou separov\u00E1ny metodou centrifugace na hustotn\u00EDm gradientu a kultivov\u00E1ny. U z\u00EDskan\u00FDch bun\u011B\u010Dn\u00FDch lini\u00ED bude provedena z\u00E1kladn\u00ED charakterizace za pomoci imunohistochie, western-blotingu, fluorescen\u010Dn\u00ED a konfok\u00E1ln\u00ED mikroskopie, \u010Dasosb\u011Brn\u00E9 videomikroskopie a pr\u016Ftokov\u00E9 cytometrie. Vybran\u00E9 bun\u011B\u010Dn\u00E9 linie budou n\u00E1sledn\u011B ovlivn\u011Bny pod\u00E1n\u00EDm bevacizumabu nebo cetuximabu, kdy budou sledov\u00E1ny rozd\u00EDly mezi bu\u0148kami ovlivn\u011Bn\u00FDmi a kontroln\u00EDmi. V budoucnu by bylo mo\u017En\u00E9 srovn\u00E1n\u00ED proteomick\u00E9ho profilu n\u00E1dorov\u00FDch bun\u011Bk od jednotliv\u00FDch pacient\u016F a tak\u00E9 porovn\u00E1n\u00ED reakce na c\u00EDlenou terapii u samotn\u00FDch pacient\u016F. V\u00FDsledky by m\u011Bly p\u0159isp\u011Bt k porozum\u011Bn\u00ED efektu t\u00E9to l\u00E9\u010Dby na n\u00E1dorovou tk\u00E1\u0148 a n\u00E1sledn\u011B ke zlep\u0161en\u00ED indikace t\u00E9to l\u00E9\u010Dby." . "Ovlivn\u011Bn\u00ED kolorekt\u00E1ln\u00EDho karcinomu biologickou l\u00E9\u010Dbou - in vitro studie" . . "2013-05-01+02:00"^^ . . . . "1"^^ . " cancer" . "Resecated tumours from appropriate patients with colorectal carcinoma will be histopathologically examined and from the part of the tumour cancer cells will be obtained. First, the tumor cells will be cultured and the prepared cell cultures will be treated by bevacizumab and cetuximab. Subsequently, we will evaluate the changes in the phenotype of primary colorectal cancer tumor lines after stimulation with these agents in order to describe effect on the biological profile of the cells. Samples of these cell lines will be deeply frozen for the further proteomic analysis. Prospectively, in the second phase we would try to identify differences in proteome among the cell lines from patients who responded to the treatment by the particular drug from those where the treatment failed. As a result we would detect the differences both biological both proteomic which may be relevant for the future optimization and individualization of therapy."@en . "0"^^ . "http://www.isvav.cz/projectDetail.do?rowId=NT14150"^^ . . "0"^^ . . "colorectal" . "2015-12-31+01:00"^^ . . "0"^^ . "0"^^ . "NT14150" . " primary lines" . . . . . "colorectal; cancer; primary lines; targeted therapy"@en .